Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4946627 | 0.87 | ERN1 (0.72) | ERN1HTTMAPTALDH1A1LMNA | |
| SCHEMBL11683169 | 0.84 | ERN1 (0.68) | ERN1PTGS2HTTMAPTALDH1A1 | |
| SCHEMBL10325884 | 0.82 | HTT (0.51) | ERN1ALOX5PTGS2HTTMAPT | |
| SCHEMBL994720 | 0.81 | MEN1 (0.56) | HTTMAPTALDH1A1LMNAMEN1 | |
| Methoxymethane SCHEMBL29098909 | 0.81 | ALDH1A1 (0.55) | ERN1PTGS2HTTMAPTALDH1A1 | |
| SCHEMBL8580120 | 0.81 | ERN1 (0.64) | ERN1HTTMAPTALDH1A1LMNA | |
| SCHEMBL17132381 | 0.81 | HTT (0.50) | ERN1PTGS2HTTMAPTALDH1A1 | |
| SCHEMBL11577328 | 0.81 | ERN1 (0.64) | ERN1HTTMAPTALDH1A1LMNA | |
| SCHEMBL28959524 | 0.79 | ERN1 (0.62) | ERN1PTGS2HTTMAPTALDH1A1 | |
| SCHEMBL28505699 | 0.79 | HTT (0.49) | ERN1PTGS2HTTMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110698352-B | Synthetic method of 3-bromo-5-aminocatechol dimethyl ether | 邢台学院 | 2023-01-17 | — | — | CN | claimed |
| CN-110698352-A | Synthetic method of 3-bromo-5-aminocatechol dimethyl ether | 邢台学院 | 2020-01-17 | — | — | CN | claimed |
| US-12545716-B2 | Immunoconjugates and methods | IMMUNOME, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12285492-B2 | Immunoconjugates and methods | IMMUNOME, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-12280121-B2 | Immunoconjugates and methods | IMMUNOME, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-12274754-B2 | Immunoconjugates and methods | IMMUNOME, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-12268750-B2 | Immunoconjugates and methods | IMMUNOME, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-12186403-B2 | Immunoconjugates and methods | IMMUNOME, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240424122-A1 | IMMUNOCONJUGATES AND METHODS | ZENO MANAGEMENT, INC. | 2024-12-26 | — | — | US | disclosed |
| US-20240424121-A1 | IMMUNOCONJUGATES AND METHODS | ZENO MANAGEMENT, INC. | 2024-12-26 | — | — | US | disclosed |
| US-20240424124-A1 | IMMUNOCONJUGATES AND METHODS | ZENO MANAGEMENT, INC. | 2024-12-26 | — | — | US | disclosed |
| CN-110698352-A | Synthetic method of 3-bromo-5-aminocatechol dimethyl ether | 邢台学院 | 2020-01-17 | — | — | CN | disclosed |
| US-9410958-B2 | Alkyne-activated fluorogenic azide compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150276752-A1 | ALKYNE-ACTIVATED FLUOROGENIC AZIDE COMPOUNDS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-01 | — | — | US | disclosed |
| EP-2470022-A1 | COMPOUNDS AND METHODS | GlaxoSmithKline LLC (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120157482-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-06-21 | — | — | US | disclosed |
| US-20120157482-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-06-21 | — | — | US | disclosed |
| US-20120157482-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-06-21 | — | — | US | disclosed |
| WO-2011025798-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011025798-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424122-A1 | IMMUNOCONJUGATES AND METHODS | CD4, L1CAM, PDCD1LG2 | ERN1 4075/4885ALOX5 3632/4885PTGS2 4008/4885 |
| US-12280121-B2 | Immunoconjugates and methods | CD4, L1CAM, PDCD1LG2 | ERN1 4075/4885ALOX5 3632/4885PTGS2 4008/4885 |
| US-20150276752-A1 | ALKYNE-ACTIVATED FLUOROGENIC AZIDE COMPOUNDS AND METHODS OF USE THEREOF | ALK, DNPEP, ACR | ERN1 2168/4885ALOX5 2728/4885PTGS2 4782/4885 |
| US-12186403-B2 | Immunoconjugates and methods | CD4, L1CAM, PDCD1LG2 | ERN1 4075/4885ALOX5 3632/4885PTGS2 4008/4885 |
| US-12545716-B2 | Immunoconjugates and methods | FCGR3B, FCGR2A, LY6K | ERN1 3795/4885ALOX5 2861/4885PTGS2 4024/4885 |
| US-20240424121-A1 | IMMUNOCONJUGATES AND METHODS | CD4, L1CAM, PDCD1LG2 | ERN1 4075/4885ALOX5 3632/4885PTGS2 4008/4885 |
| US-12285492-B2 | Immunoconjugates and methods | CD4, L1CAM, PDCD1LG2 | ERN1 4075/4885ALOX5 3632/4885PTGS2 4008/4885 |
| US-12268750-B2 | Immunoconjugates and methods | CD4, L1CAM, PDCD1LG2 | ERN1 4075/4885ALOX5 3632/4885PTGS2 4008/4885 |
| US-12274754-B2 | Immunoconjugates and methods | CD4, L1CAM, PDCD1LG2 | ERN1 4075/4885ALOX5 3632/4885PTGS2 4008/4885 |
| US-20240424124-A1 | IMMUNOCONJUGATES AND METHODS | CD4, L1CAM, PDCD1LG2 | ERN1 4075/4885ALOX5 3632/4885PTGS2 4008/4885 |
| US-20120157482-A1 | COMPOUNDS AND METHODS | NQO1, CYP1B1, CYP1A1 | ERN1 3124/4885ALOX5 847/4885PTGS2 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.